Resistance to Cotrimoxazole and Other Antimicrobials among Isolates from HIV/AIDS and Non-HIV/AIDS Patients at Bugando Medical Centre, Mwanza, Tanzania

Table 5

Predictors of ESBL producing isolates among 155 clinical isolates.

	ESBL nonproducer	ESBL producer		Crude
	%	%		OR (95% CI)
Cotrimoxazole
Resistant	83 (69.8)	35 (97.2)	0.001	1
Susceptible	36 (30.2)	1 (2.8)		15 (1.85–125 .5)
Amoxycillin-clavulanic
Resistant	35 (31.3)	35 (100)	<0.001	NA
Susceptible	77 (68.7)	0. (0.0)
Ciprofloxacin
Resistant	14 (12.9)	22 (75.9)	<0.001	1
Susceptible	95 (87.1)	7 (24.1)		0.05 (0.01–0.13)
Ampicillin
Resistant	71 (72.5)	29 (100)	0.001	NA
Susceptible	27 (27.5)	0 (0.0)
Tetracycline
Resistant	47 (73.4)	30 (100)	0.002	NA
Susceptible	17 (26.6)	0 (0.0)
Ceftriaxone
Resistant	19 (47.5)	15 (83.3)	0.01	1
Susceptible	21 (52.5)	3 (16.7)		5.52 (1.26–24.4)
HIV status
Negative	64 (53.8)	19 (52.8)	0.92	1
Positive	55 (46.2)	17 (47.2)		1.04 (0.49–2.19)
Cotrimoxazole prophylaxis
No	23 (41.9)	5 (29.4)	0.36	1
Yes	32 (58.1)	12 (70.6)		1.72 (0.53–5.57)